Can cancer patients get their infusions in less time? new study aims to find out
NCT ID NCT06031233
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study is testing whether giving several common cancer immunotherapy drugs over a shorter time is safe. It involves 776 adults starting treatment with drugs like nivolumab or pembrolizumab. Infusion times will be gradually shortened if patients tolerate it well, and researchers will monitor for infusion reactions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab, pembrolizumab, ipilimumab, durvalumab, atezolizumab, bevacizumab, trastuzumab, rituximab
What this could lead to
If successful, this could allow cancer patients to receive their immunotherapy infusions in a shorter time, making treatment more convenient.
What could go wrong
This is an early-phase observational study, so results may not apply to all patients. There is a risk of infusion reactions with faster delivery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ONCOLOGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Isala Hospital
RECRUITINGZwolle, 8025AB, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••